Structured pharmaceutical care improves the health-related quality of life of patients with asthma

Philip O. Anum1*, Berko P. Anto2 and Audrey G. Forson3

Abstract

Background: Asthma as a chronic health condition can be controlled when in addition to clinical care, adequate education and support is provided to enhance self-management. Like many other chronic health conditions improved self-management positively impacts the health-related quality of life (HRQoL). It can therefore be said that a well-structured pharmaceutical care delivery that addresses the issues related to patient education and support towards self-management stands a good chance of positively impacting asthma control. This study evaluated the impact of a structured pharmaceutical care delivery on asthma control.

Methods: A prospective pre-/post- intervention study of a single cohort of 77 adult out-patients visiting specialist asthma clinics in Ghana were assessed for HRQoL and peak expiratory flow rates (PEFR) one month after pharmaceutical care intervention. Pharmaceutical care intervention covered education on the health condition, pharmacotherapy and self-management issues as well as correction of inhaler-use technique, where necessary and when to urgently seek medical care. The mean difference of the HRQoL and PEFR values were subjected to paired samples t-test analysis.

Results: Delivery of a structured pharmaceutical care led to a significant improvement in asthma specific quality of life and PEFR. The mean paired difference of the HRQoL for a cohort of patients with asthma post- pharmaceutical care intervention was 0.697 (95% CI: 0.490 - 0.900) at $t = 6.85$ ($p < 0.05$). The mean paired difference for PEFR post intervention was 17.533 (95% CI: 2.876 - 32.190) at $t = 2.384$ ($p = 0.02$).

Conclusion: This study identified important challenges with both the pharmacologic and the non-pharmacologic management of adult asthma patients. Inadequate inhaler-use skills, widespread occurrence of preventable adverse events and irregular use of preventer medicines were prevalent among patients. At one month after pharmaceutical care intervention, patients with asthma in a cohort follow-up study showed significant improvements with regard to asthma-specific quality of life, peak flow rates and knowledge.

Keywords: Asthma, Health-related Quality of Life, Pharmaceutical Care
14 year age group and with decreases in prevalence in Western Europe [3]. The results however, indicated increases in prevalence in regions where prevalence was previously low, such as in Africa and parts of Asia [3]. These indications of growing trends of asthma in Africa were corroborated by Adeloye and colleagues [4] who also estimated a rising asthma prevalence in Africa, to be in the region of about 74 million to 119.3 million over the past two decades (1990–2010). The incidence rate of asthma in Ghana has however been estimated at 1.5/1000 per year by the WHO [5].

Notwithstanding these levels of occurrence, most health care systems are still organised around the acute care model which does not meet the management needs of patients with NCDs. The WHO-Innovative Care for Chronic Conditions report (2002) has suggested that supported self-management with regular follow-ups in addition to effective treatments improves the outcomes for chronically ill patients [6].

The mainstay for asthma management that conforms to this innovative care for NCDs is the continuous monitoring of the patient for asthma control and therapy adjustments that are intended to minimize the symptoms regardless of the severity of the condition [7, 8]. Studies performed by Juniper and colleagues [9] have shown close correlation between the values of the Health-Related Quality of Life (HRQoL) of asthma patients and the levels of their asthma control. On the basis of these advances, various studies on asthma have used the HRQoL to assess the impact of interventions.

These trials, and especially those related to determination of effect of patient education by pharmacists on the outcomes of the disease have shown mixed results [10–16]. Some of these studies have indicated improvements in patient symptom scores [15], quality of life measurements, [15, 17–19] asthma severity [15, 17] and PEFR [15, 17, 19]. The extent of the interventions was broad and may have introduced some bias into these studies. Various levels of bias could have been introduced from the drug therapy interventions and PEFR assessments and interpretations from the skills of the pharmacists at the multiple sites for the interventions. Some studies used only asthma severity [15] as primary outcomes measure, while others investigated only some aspects of asthma control [17]. Some of the studies protracted beyond 3 months, [15, 17–19] but did not reasonably resolve the issues of sustainability in such a chronic disease that is influenced by numerous intrinsic and extrinsic factors. The GINA [7] recommendations with regards to continuous monitoring and adjustments of therapy towards asthma control should apply here for pharmacy interventions as well.

Furthermore most of these studies used case–control methods in community settings where the participants in the “case” group cannot be totally isolated from those in the “control” group of the study. In cases where education impacts outcome, then it must be ensured that there is no exchange between the “case” and “control” participants.

It is for these reasons that this researchers opted for a single cohort study and fewer sites to allow only two trained pharmacists to undertake the interventions. The interventions were also only focused on patient understanding of the disease condition, the medications and the appropriate use of the prescribed medications. The study employed the use of the HRQoL instrument as the primary outcome measure of asthma control. Secondary outcomes were the measurements of PEFR and inhalation technique scores. This cohort trial was organised to study the hypothesis that provision of organised pharmaceutical care that focussed on patient education on prescribed medications, would improve asthma control in adult patients.

Methods

Design

A prospective pre-/post- intervention study of a single cohort of adult out-patients visiting specialist asthma clinics in Ghana were assessed for HRQoL and peak expiratory flow rates (PEFR) at baseline and one month after pharmaceutical care intervention. Pharmaceutical care intervention covered education on the health condition, pharmacotherapy and self-management issues as well as correction of inhaler-use technique, where necessary and self-referral for early unscheduled review for worsening asthma condition. The mean differences in HRQoL and PEFR values were subjected to a paired samples t-test analysis.

Setting

Four out-patient clinical sites were used in the study. Two were teaching hospitals that managed referral cases from various health institutions and run specialist asthma clinics once a week. The two other hospitals were not teaching hospitals, but one runs specialist asthma clinics. All the clinical sites were located within the southern and middle belts of Ghana.

Sample-size estimation

Assuming a mean HRQoL difference size of 0.5 (the minimum important difference of clinical significance) [20] and a standard deviation of HRQOL score of 0.8 from previous studies in the literature, the calculated standardized effect size (the mean difference / standard deviation) was estimated to be approximately 0.6. To estimate the sample size to test the hypothesis, a power (β) of 0.9 and the level (two-sided) of statistical significance (α) of 0.05 were set. Using these settings, the estimated
sample size required for the cohort, when using the paired samples t-test to compare means of continuous variables to determine the minimum important difference of 0.5 was 60 patients. A convenience sample of 92 patients was used recruited for the study.

Data collection instrument
Two sets of data collection instruments were used in this study. The Model Pharmaceutical Care Instrument was used to collect data on participant demographics, medication profile, inhaler-use technique, perceived adverse medication events, peak expiratory flow rates symptoms and environmental trigger factors. This was used to guide participant education. Review of this data identified care needs of every participant in the study. Care needs addressed included: understanding of disease condition and the role of the various medications; inhaler-use technique; issues of medication adherence; availability of medications; management of trigger factors; management of adverse events, and peak flow meter assessment of lung function.

The standard Asthma Quality of Life Questionnaire (AQLQ(S)) and the Peak Expiratory Flow Meter (“Airzone” flow meter by Clement Clarke International) were used to assess participant HRQoL and lung function pre and post pharmaceutical care intervention. It was adopted to measure the functional problems (physical, emotional, social and occupational) that are most troublesome to adults (17–70 years) with asthma. The AQLQ(S) is an asthma-specific instrument that had been validated in clinical trials [21]. The AQLQ(S) contains 32 questions (items) comprising four domains: Activity Limitations, Asthma Symptoms, Emotional Function and Environmental Exposure. Each item was scored based on a 2-week recall of activities on a 7-point Likert scale with Point 1 indicating severe impairment and point 7 indicating no impairment. The overall score for HRQoL was the mean score of the 32 items.

A change in mean overall or domain score of 0.5 had been shown to represent the smallest change of importance to the patient (the “minimal important difference”), and a change in score of 1.0 represents a moderate change [20]. However, a maximum overall AQLQ(S) score of 7 represents no impairment in QOL due to asthma, and scores approaching 7 imply a minimal impact of asthma on QOL.

Ethical clearance
Having obtained an ethical clearance from the Ghana Health Service (GHS-ECH: 08/9/11) and participant consent, ninety two (92) adults with symptomatic asthma, without other active co-morbidities, who visited the outpatient clinic, were recruited into the study.

Data collection and intervention
Asthma patients attending regular clinical review in 4 selected hospitals located in the middle and southern belts of Ghana were recruited into the study. Eligibility for participation was limited to patients aged 17–70 years who have been medically diagnosed with asthma and had no active co-morbidities. Excluded in the study were patients whose medications were changed in their previous review visit prior to the recruitment. After giving their consent to participate in the study, a convenience sample of 92 patients was selected by

| Table 1 | Background characteristics of participants at baseline | Participants % |
|---------|-------------------------------------------------------|----------------|
| Education (n = 77) | | |
| Primary School | 26 |
| High School | 48.1 |
| Tertiary | 49.4 |
| Symptoms Occurrence (n = 77) | | |
| Less than or 2 days in a week | 71.4 |
| More than 2 days per week but not daily | 16.9 |
| Daily occurrence | 11.7 |
| Night-time Awakenings (n = 77) | | |
| Less than two times in a month | 67.5 |
| Three to four times in a month | 15.6 |
| More than once in a week, but not every night | 16.9 |
| Use of Reliever Medications for Control (n = 77) | | |
| Less than or 2 days in a week | 58.4 |
| More than two days in a week but not daily | 23.4 |
| Daily use | 18.2 |
| Adherence to Prescribed Preventer Medications (n = 69) | | |
| Regular usage | 56.5 |
| Irregular usage | 43.5 |
| Adverse Drug Events Reported (n = 77) | | |
| Yes | 42.9 |
| No | 57.1 |
| Reported Adverse Events with Preventer Medications (n = 69) | | |
| Regular Preventer Medicine Usage with Adverse Events | 48.7 |
| Regular Preventer Medicine Usage with No Adverse Events | 51.3 |
| Irregular Preventer Medicine Usage with Adverse Events | 40.0 |
| Irregular Preventer Medicine Usage with No Adverse Events | 60.0 |
selecting 10 patients out of a mean attendance of 30 patients per week from 4 hospitals for a period of 12 weeks. These participants were administered with the baseline questionnaires and provided educational intervention. These participants were followed up one month after the interventions. Fifteen (15) participants were lost to follow up. They did not show up for the post-intervention assessments. Therefore data for a total number of 77 patients from the baseline intervention were used for analysis.

Two clinical pharmacists, who were trained for the study, undertook the patient assessment and provided educational intervention. The HRQoL instrument was self-administered by participants. All other participant data was collected with the “Model Pharmaceutical Care” forms. The best of 3 PEFR assessments were entered for each participant. The total score for inhaler-use technique was collated for each participant. Inhaler-use technique score was the sum of one (1) point per each correct step undertaken by participant and observed by the study pharmacist. The maximum total of 7-points score marks were based on the extension of the manufacturers’ inhalation steps as found in product leaflets. Based on their inhaler-use technique scores, participants were coached to perform all the steps correctly. The “Model Pharmaceutical Care” forms were used to administer questionnaire on “perceived” environmental trigger factors on individual participant’s asthma and adverse effects from their prescribed medications. The impact of asthma with regards to airway narrowing and the roles of “reliever” and “preventer” medicines on the airways were explained to each participant. Participant’s knowledge, PEFR and HRQoL were consecutively re-assessed in one month after the provision of the interventions.

Data analysis
Data from the study were subjected to both descriptive and inferential statistical analysis. Data were analyzed to generate various tables and charts to demonstrate similar themes, frequencies, trends and number counts under the following themes:

- Baseline Characteristics of Asthma Out-patient Clinic Participants
- Comparison of Asthmatic Patients’ Characteristics Post Pharmaceutical Care Intervention

Data collected demonstrated normal distribution with same values for central tendency. Data were therefore analyzed to test the study hypothesis using a paired

| Table 2 Incidence of adverse events reported by participants |
|-------------------------------------------------------------|
| Adverse Events       | Number of Participants | Adverse Events       | Number of Participants |
|----------------------|------------------------|----------------------|------------------------|
| Coughs               | 8                      | Headache             | 2                      |
| Dry Mouth            | 6                      | Palpitations         | 1                      |
| Light Headedness     | 3                      | Sweating             | 1                      |
| Chest Burns          | 3                      | Phlegm               | 1                      |
| Sore Throat          | 3                      | Nasal Congestion     | 1                      |
| Itching              | 3                      | Blurred Vision       | 1                      |
| Sneeze               | 2                      | Pins & Needles       | 1                      |
| Nausea               | 2                      | Neck Pains           | 1                      |

| Table 3 Participant asthma medication profile |
|-----------------------------------------------|
| Inhaled Medication(s) | Number of Participants (%) | Patients on Prednisolone with Inhaler Medication(s) |
|------------------------|----------------------------|-----------------------------------------------------|
| Salbutamol Only        | 5 (6.5)                    | -                                                   |
| Salbutamol + Beclomethasone | 1 (1.3) | -                                                   |
| Salbutamol + Pulmicort | 8 (10.4)                   | 1                                                   |
| Salbutamol + Budesonide/Formoterol | 37 (48.1) | 2                                                   |
| Salbutamol + Fluticasone/Salmeterol          | 22 (28.6)                  | 3                                                   |
| Budesonide/Formoterol only                     | 2 (2.6)                    | -                                                   |
| Fluticasone/Salmeterol only                    | 1 (1.3)                    | -                                                   |
| Salbutamol + Fluticasone/Salmeterol + Ipratropium | 1 (1.3) | 1                                                   |
samples t-test; the mean differences in the baseline and post pharmaceutical care intervention HRQoL were analyzed.

Results

General background characteristics at baseline

Study participants were predominantly female (61%) and had a mean age of 46 (±15) years. The mean peak expiratory flow rate was 284(±103) for the 77 participants. Most participants in the study had a minimum of high school education (97.5%) as in Table 1. The daily symptoms occurrence (11.7%) and the night-times awakenings (16.9%) frequencies were similar to reliever medication usage rates (18.2%), however there was a high irregular use (43.5%) of preventer medications (Table 1). Many participants (42.9%) reported one form or the other of various adverse events perceived to be associated to their asthma medicines.

Incidence of adverse events

Participants reported of widespread incidence of adverse drug events perceived to by associated with their asthma medications. Coughs and dry mouth were the most frequently reported incidence of events (Table 2).

Participants’ inhaler medication profile

Almost all participants (96%) used Salbutamol inhalers. In addition, Budesonide/formoterol (51%) and Fluticasone/salmeterol (31%) inhalers were used in various combinations (Table 3).

Table 4 presents the number of years participants had used various inhaler types. While 42% of participants had used “Reliever” inhalers for 10 years or more, only 4% of participants had used “Preventer” inhaler for that long. However, 55% of participants had used a “Preventer” for a minimum of one year. Some 6 participants on “Reliever” inhalers and 7 other participants on “Preventer” inhalers could not recollect for how long they had used these medicines.

Participants’ inhaler-use technique

Baseline inhaler-use technique score captured using an inhaler-use technique assessment questionnaire, shown in Table 5 indicate that only 12% and 17% of participants on dry powder inhalers (DPI) and metered dose inhalers (MDI) respectively scored the maximum score of 7 points. The mean inhaler-use technique scores were 4.66 (1.3) for the use of DPIs and 5.03(1.43) for the use MDIs.

Environmental trigger-factors affecting participants

Dust (78%), perfume/and strong scents (78%) and smoke (70%) were the most commonly mentioned environmental trigger-factors that worsened the asthma of participants (Table 6). Other trigger-factors like room air-conditioning, fresh cut grass, and alcohol and beer intake affected about 5% of participants.

Post-pharmaceutical care comparison of participant characteristics

The quantum of change in HRQoL is displayed in Table 7. About 56% of participants had a positive change in HRQoL, while 9% had a negative change after the pharmaceutical care intervention. However, about 35% of participants had changes that were not significant.

From Table 8, the paired mean difference values for the HRQoL and all the domains were above 0.5, the mean important difference. The overall paired mean difference for the HRQoL at 95% CI was 0.697 (0.490-0.900) at 95% CI, with a T- value of 6.845 (2-tailed p < 0.001). The paired mean difference at 95% CI was highest for the Symptoms domain 1.134 (0.910 – 1.360) and lowest for the Activity Limitation domain 0.548 (0.340 - 0.760).

The mean (PEFR) at baseline was 266.5 L/min (SD 85.9), which increased to 284.0 L/min (SD 103.3) after the intervention (Table 9). The paired mean difference between baseline and post-pharmaceutical care intervention PEFR was 17.5 L/min. (95% CI: 2.876-32.190, p < 0.05).

Table 4 Participant inhaler medication usage

| Years of Inhaler Usage | Participant’s Inhaler Type (n = 77) | Reliever (%) | Preventer (%) |
|------------------------|-------------------------------------|--------------|--------------|
| ≥10 years              | 31 (42.3)                           | 3 (3.9)      |
| 6 – 9 years            | 8 (10.4)                            | 7 (9.1)      |
| 1-5 years              | 27 (35.1)                           | 42 (54.5)    |
| ≤1 year                | 5 (6.5)                             | 18 (23.4)    |
| Cannot recollect       | 6 (7.8)                             | 7 (9.1)      |

Table 5 Participant inhaler-use technique score

| Inhaler Type | Inhaler-use Technique Score (7-point scale) | Percentage with Adequate Technique | Mean Score (SD) |
|--------------|---------------------------------------------|-----------------------------------|-----------------|
| DPI (n = 66) | 1 2 3 4 5                                     | 12.12                             | 4.66(1.3)       |
| MDI (n = 63) | 0 4 3 13 19                                   | 17.46                             | 5.03(1.43)      |

*DPI dry powder inhaler, *MDI metered dose inhaler
Table 6 Number of participants affected by environmental trigger-factors

| Trigger-factor type          | Participants Affected (n = 77) | Frequency (%) |
|-----------------------------|--------------------------------|---------------|
| Dust                        | 60                             | 77.92         |
| Perfume /Scent              | 60                             | 77.92         |
| Smoke                       | 54                             | 70.13         |
| Food / Spices               | 21                             | 27.27         |
| Weather Changes             | 19                             | 24.68         |
| Stress / Tiredness/Emotions | 14                             | 18.18         |
| Cold Drinks                 | 11                             | 14.29         |
| Others (beer, fresh cutting grass, alcohol & air-conditioner) | 4                 | 5.19          |

Discussion

Overall participant Inhaler-use technique assessments revealed low scores. Over half of participants in this study had used Salbutamol metered-dose inhaler for more than 5 years, and yet very few had adequate inhaler-use technique to either the dry powder type of inhalers or the metered dose type of inhalers. It is possible that most of the participants had progressed up the therapeutic steps to the use of Salbutamol with Budesonide/formoterol or Fluticasone/salmeterol (step 3) as a result of poor asthma control due to inadequate use of inhalers. In conformity with third Expert Panel Review (EPR-3, 2007) and Global Initiative for Asthma (GINA, 2014) recommendations, usually after a 3-month period of well-controlled asthma there should have been a step down in therapy, [7, 21] but only 12% of patients were on ICS inhalers alone as controller medication. Poor inhaler-use technique and/or poor compliance could be the reason why patient’s asthma was not stable enough to be stepped down. The GINA guidelines have suggested that before increasing pharmacologic therapy, one must first consider poor inhaler technique, poor adherence and co-morbidities as targets for intervention [7].

The degree of poor inhaler-use technique identified among study participants indicates that not enough consideration has been given to the role of inhaler-use technique in patient management. It further suggests that there is insufficient patient education and counselling at the clinic and at the pharmacy, and that any education and counselling provided to the study participants in the past clearly did not adequately impact on their skills, or its impact might have diminished with time.

The common major environmental trigger-factor affecting participants in this study were exposure to dust, smoke and perfume or strong scents, which suggests that another major need for intervention is education on the improved control of environmental triggers by patients within their environment.

Previous studies by Mangiapane, and colleagues [18], using a single cohort design, observed significant changes in both HRQoL, and PEFR, among others. This study also, using a single cohort design found significant changes in the HRQoL and the PEFR. Whilst more than half of the study participants’ perceived improvements in HRQoL, 9% of them perceived worsened HRQoL and 35% did not perceived any changes in their HRQoL. Though no factual reasons could be assigned immediately, issues related to patient adherence to inhaler medications and the influence of environmental trigger-factors may have played a role. However, the deterioration and the non-significant change in HRQoL might also be explained by the “pheno-type of asthma theory”. The EPR-3 [8] suggests that very specific patterns of inflammation exist in some individuals that require different treatment approaches in addition to the usual steroid-based anti-inflammatory treatment.

The paired mean difference values for the overall general HRQoL and its various domains were both clinically and statistically significant, showing benefit of the pharmaceutical care intervention to the patients in all aspects of their quality of life. The Symptoms domain had the highest mean change difference of 1.134 (95% CI: 0.910 - 1.360) and the Activity Limitation had the lowest of 0.548 (95% CI: 0.340 – 0.760). This is an indication that the various domains were impacted to different extents within the composite overall HRQoL. Barbanel and colleagues [13] did not use the HRQoL as the outcomes measure when they studied the impact of pharmacists’ intervention on asthma patients. They used asthma symptoms and observed significant improvements. This study also observed more significant improvements within the symptoms domain than the other various domains that constituted the composite HRQoL.

However, Mancuso and colleagues [22] found out that these favourable results from pharmacy interventions...
tended to wane with time if follow-ups were not pursued with participants, as may have been the case with our patients.

This study observed improvements in participants’ values at the end of the intervention as with their HRQoL when PEFR measurements were used as a secondary measure of asthma control. However, analytical exploration of the values indicated only a weak positive correlation between the changes in the overall HRQoL and PEFR from baseline as a result of the intervention. Previous studies by [15, 19] among others, also observed significant improvements in the PEFR within the intervention groups. PEFR are known to have an a diminished correlation with the FEV1 in patients with asthma, [23] however the EPR- 2007 recommends PEFR monitoring, using the patient’s best peak flow in an asthma action plan [21]. The weak correlation between the PEFR with the HRQoL therefore is a reflection of their controversial role in assessing airway obstruction rather than voluntary effort and muscular strength of the patient [23].

Outstanding are the economic implications of such intervention on the cost of asthma management. Further to any clinical significance of educational intervention, patients and health insurance schemes might make savings on asthma-related health care, cost of medications, hospitalization and emergency department visits as envisaged by [24–26]. Future studies may be needed to cost and reflect in monetary terms the savings from the impact of educational interventions in asthma.

Limitations to the study
This study has some limitations. First, the duration of the study did not allow for the participants to be followed-up further to assess duration of the impact of the intervention or to ascertain whether the therapies of the participants with significant improvements in HRQoL were subsequently adjusted in the post-intervention months. The design of this study did not factor duration of impact of the intervention since asthma is a dynamic condition that would require continuous re-evaluation and further education in conformity to the recommendations of GINA and the EPR. Secondly, the AQLQ used in the study to assess HRQoL were not translated into any of the local languages for patients who may not be able to read and write English and thereby limited the scope of patient participation. Furthermore the study covered the southern and middle belts of the country and that may to some extent also limit the overall generalizability of the findings.

Conclusion
This study identified important challenges with both the pharmacologic and the non-pharmacologic management of adult asthma patients. Inadequate inhaler-use skills, widespread occurrence of preventable adverse events and

| Table 8 | Paired mean difference statistics of the health related quality of life of participants after intervention |
|---------|--------------------------------------------------------------------------------------------------------|
| Health-Related Quality of Life Domain | Mean (SD) | Paired Differences | Mean (SD) | 95% CI of the Difference | T | DF | Sig. (2-tailed) |
| HRQoL | Pre- 4.15 (1.132) | 0.697 (0.891) | 0.490 | 0.900 | 6.845 | 76 | 0.000 |
| Post- 4.85 (1.271) | | | | | |
| Activity Limitation | Pre- 4.37 (1.143) | 0.548 (0.921) | 0.340 | 0.760 | 5.256 | 76 | 0.000 |
| Post- 4.92 (1.224) | | | | | |
| Symptoms | Pre- 3.998 (1.086) | 1.134 (0.985) | 0.911 | 1.358 | 10.104 | 76 | 0.000 |
| Post- 5.132 (1.304) | | | | | |
| Emotional Function | Pre- 3.907 (1.453) | 0.714 (0.938) | 0.501 | 0.927 | 6.684 | 76 | 0.000 |
| Post- 4.621 (1.583) | | | | | |
| Environmental Stimuli | Pre- 3.289 (1.562) | 0.776 (1.099) | 0.526 | 1.025 | 6.195 | 76 | 0.000 |
| Post- 4.065 (1.685) | | | | | |

| Table 9 | Paired mean difference statistics of peak expiratory flow rate after intervention |
|---------|-------------------------------------------------------------------------------------------------|
| Peak Flow Rate | Mean (SD) L/min. | Paired Differences | Mean (SD) L/min. | 95% CI of the Difference | T | DF | Sig. (2-tailed) |
| Pre- 266.467 (85.857) | 17.533 (63.705) | 2.876 | 32.190 | 2.384 | 74 | 0.020 |
| Post- 284.000 (103.294) | | | | | |
irregular use of preventer medicines were prevalent among patients. At one month after pharmaceutical care intervention, patients with asthma in a cohort follow-up study showed significant improvements with regard to asthma-specific quality of life, peak flow rates and knowledge.

Significance of pharmaceutical services in the hospital
A well-structured pharmaceutical care delivery in the hospital would contribute to patient knowledge and management and eventually improve the health-related quality of life of asthma patients. This study has shown that hospital Pharmacists would need to be properly trained to assess patients with asthma and to provide the needed education to address their individual challenges associated with the condition and the management.

Abbreviations
AQLQ(S): Standardized asthma quality of life questionnaire; DPI: Dry powder inhaler; EPR: Expert panel report; GHS: Ghana Health Service; GINA: Global initiative for asthma; HRQOL: Health related quality of life; MDI: Metered dose inhaler; NCD: Non-communicable disease; PEFR: Peak expiratory flow rate; WHO: World Health Organization; WHO-ICCC: World Health Organization-innovative care for chronic conditions; WHOQOL: World Health Organization Quality of Life

Acknowledgements
The authors wish to acknowledge the Faculty of Pharmacy, Kwame Nkrumah University of Science and Technology, the Komfo Anokye and Kole-bu Teaching hospitals, the Trust Hospital and the Cocoa Clinic for making their facilities, staff and patients available for the study. The authors wish to thank Prof. Juniper for granting us permission to use the Asthma Quality of Life Questionnaire in this study.

Funding
This self-funded study was part of a PhD project.

Availability of data and materials
The dataset used and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
POA, BPA and AGF contributed to the conception and the study design. Acquisition of data was by POA, and the analysis by POA and BPA. POA and AGF drafted the manuscript, and all authors reviewed and approved the final manuscript for submission.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
All authors have consented to the publication in this journal.

Ethics approval and consent to participate
The Ghana Health Service Ethical Review Committee reviewed and gave approval for the implementation of this study as per Ethical Clearance –ID No: GHS-ERC: 08/9/11, dated October 19, 2011. The clearance preceded the commencement of the study data collection. Prior to administering any of the study questionnaires, patients were informed about the study and those who agreed to participate were handed the study’s “Patient Consent Forms” to read and confirm their consent to participate in the study by signing the forms.

Author details
1National Drug Information Centre, Ministry of Health, Accra, Ghana. 2Department of Clinical and Social Pharmacy, Kwame Nkrumah University of Science and Technology, Accra, Ghana. 3Department of Medicine, School of Medicine and Dentistry, University of Ghana, Accra, Ghana.

Received: 2 November 2016 Accepted: 1 February 2017 Published online: 07 February 2017

References
1. WHO. Global status report on non-communicable diseases. Geneva, 2014. (http://www.who.int/nmh/publications/ncd_report_full_en.pdf) (Accessed 08 Feb 2016).
2. GINA. Global Initiative for Asthma. Global Burden of Asthma – Report. 2003. (http://www.globalasthmareport.org/burden/burden.php) (Accessed 08 Feb 2016).
3. ISAAC Group. Worldwide trends in the prevalence of asthma symptoms: Phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2007;62(9):758–66.
4. Adelyoe D, Chari KY, Rudan I, Campbell H. An estimate of asthma prevalence in Africa: a systematic review. Croat Med J. 2013;54(6):519–31.
5. WHO. Public Health and the Environment. Geneva: World Health Organization; Country Profile of Environmental Burden of Disease. Ghana. 2009. (http://www.who.int/quantifying_ehimpacts/national/countryprofile/ghana.pdf) (Assessed 05 Jan 2015).
6. WHO-ICCC. Innovative care for chronic conditions: building blocks for action World Health Organization- global report, 2002. (http://www.who.int/chp/knowledge/publications/cccreport/en/) (Accessed 10 Dec 2015).
7. GINA (Global Initiative for Asthma). Global Strategy for Asthma Management and Prevention 2014. (http://ginasthma.org/wp-content/uploads/2016/01/GINA_Report_2015_Aug11-1.pdf) (Accessed 12 Mar 2015).
8. EPR-3 (Expert Panel Report). Guidelines for the diagnosis and management of asthma (1997 report). Department of Health and Human Services; National Institutes of Health; National Heart, Lung, and Blood Institute; National Asthma Education and Prevention Program. Bethesda, MD: U.S. 2007. (https://www.nhlbi.nih.gov/health-pro/guidelines/current/asthma-guidelines/full-report) (Accessed 15 Nov 2015).
9. Juniper EF, Chauhan A, Neville E, Chatterjee A, Svensson K, Mörk AC, Ståhl E. Clinicians tend to overestimate improvements in asthma control: an unexpected observation. Prim Care Respir J. 2004;13:181–4.
10. Bynum A, Hopkins D, Thomas A, Copeland N, Irwin C. The effect of telepharmacy counseling on metered-dose inhaler technique among adolescents with asthma in rural Arkansas. Telemed J E Health. 2001;7(3): 207–17.
11. Cordina M, McElvoy JC, Hughes CM. Assessment of a community pharmacy-based program for patients with asthma. Pharmacotherapy. 2001;21(10): 1196–203.
12. Stergachis A, Gardner JS, Anderson MT, Sullivan SD. Improving pediatric asthma outcomes in the community setting: does pharmaceutical care make a difference? J Am Pharm Assoc (Wash). 2002;42(5):743–52.
13. Barbanell D, Eldridge S, Griffiths C. Can a self-management programme delivered by a community pharmacist improve asthma control? A randomized trial. Thorax. 2003; 58(10):851–4.
14. McLean W, Gillis J, Waller R. The BC Community Pharmacy Asthma Study: a study of clinical, economic and holistic outcomes influenced by an asthma care protocol provided by specially trained community pharmacists in British Columbia. Can Respir J. 2003;10(4):195–202.
15. Saini B, Kass I, Armour C. Development, implementation, and evaluation of a community pharmacy-based asthma care model. Ann Pharmacother. 2004;38(11):1954–60.
16. Bhatki IA, Reddal HK, Armour CL, Bosnic-Anticevich SZ. Counseling about turbuhaler technique: needs assessment and effective strategies for community pharmacists. Respir Care. 2005;50(5):617–23.
17. Armour C, Bosnic-Anticevich S, Brilliant M, Burton D, Emmerton L, Kass I, Saini B, Smith L, Stewart K. Pharmacy Asthma Care Program (PACP) improves outcomes for patients in the community. Thorax. 2007;62:496–502.
18. Mangiapane S, Schulz M, Muhlig S, Hele P, Schubert I, Waldmann HC. Community pharmacy-based pharmaceutical care for asthma patients. Ann Pharmacother. 2005;39(11):1817–22.
19. Schulz M, Verheyen F, Muhlig S, Muller JM, Muhlbaeuer K, Knop-Schneickert E, Petermann F, Bergmann KC. Pharmaceutical care services for asthma patients: a controlled intervention study. J Clin Pharmacol. 2001;41:668–76.
20. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life instrument. J Clin Epidemiol. 1994;47:81–7.
21. EPR-3 (Expert Panel Report). Guidelines for the diagnosis and management of asthma—a report. Bethesda, Maryland: Department of Health and Human Services; National Institutes of Health; 2007.

22. Mancuso CA, Sayles W, Allegrante JP. Randomized trial of self-management education in asthmatic patients and effects of depressive symptoms. Ann Allergy Asthma Immunol. 2010;105:12–9.

23. Neuspiel DR. Peak flow rate measurement—Medscape (http://emedicine.medscape.com/article/1413347-overview) [Accessed 08 Feb 2015].

24. Teach SJ, Crain EF, Quint DM, Hylan ML, Joseph JG. Improved asthma outcomes in a high-morbidity pediatric population: results of an emergency department–based randomized clinical trial. Arch Ped Adolesc Med. 2006;160(5):535–51.

25. Cicuto L, Murphy S, Coutts D, ORourke J, Lang G, Chapman C, Coates P. Breaking the access barrier: evaluating an asthma center’s efforts to provide education to children with asthma in schools. Chest. 2005;128(4):1928–35.

26. Morgan WJ, Crain EF, Gruchalla RS, O’Connor GT, Kattan M, Evans R III, Stout J, Malindzak G, Smartt E, Plaut M, Walter M, Vaughn B, Mitchell H. Inner-City asthma study group. Results of a home-based environmental intervention among urban children with asthma. N Engl J Med. 2004;351(11):1068–80.